Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has drawn a 'Buy' rating from financial firm Rodman & Renshaw, which initiated coverage with an $8.00 price target based on the potential of the company's lead drug candidate, Lucid-MS. This endorsement highlights the promise of Lucid-MS as a potentially first-in-class non-immunomodulatory small molecule designed to combat neurodegeneration and disability progression in progressive multiple sclerosis (MS), a condition where current therapeutic options are limited.
The $8.00 price target reflects the firm's valuation of Quantum BioPharma's development pipeline, with Lucid-MS at the forefront. The drug candidate is being developed to address the underlying mechanisms of MS, specifically targeting myelin degradation, which is central to the disease's progression. In preclinical models, Lucid-MS has shown the ability to prevent and reverse myelin degradation, offering hope for patients who currently have few treatment alternatives.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of Lucid-MS, a patented new chemical entity. The company's pipeline includes drug candidates at various stages of development, reflecting its commitment to addressing significant unmet medical needs.
In addition to its work on Lucid-MS, Quantum BioPharma has also developed UNBUZZD(TM), a product aimed at alcohol misuse, and has spun out its OTC version to Unbuzzd Wellness Inc. (UWI). Quantum retains a 19.48% ownership stake in UWI as of June 30, 2026, and is entitled to royalty payments of 7% of sales from UNBUZZD(TM) until total payments reach $250 million, after which the royalty rate drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
For more information on Lucid-MS, visit https://nnw.fm/8uqwL.
The latest news and updates relating to QNTM are available in the company's newsroom at https://nnw.fm/QNTM.
